Evrópusambandið - íslenska - EMA (European Medicines Agency)

pfizer europe ma eeig - respiratory syncytial virus, subgroup a, stabilized prefusion f protein / respiratory syncytial virus, subgroup b, stabilized prefusion f protein - sýkingar af völdum sýklalyfja - bóluefni - abrysvo is indicated for:passive protection against lower respiratory tract disease caused by respiratory syncytial virus (rsv) in infants from birth through 6 months of age following maternal immunisation during pregnancy. sjá kafla 4. 2 og 5. active immunisation of individuals 60 years of age and older for the prevention of lower respiratory tract disease caused by rsv. notkun þetta bóluefni ætti að vera í samræmi við opinbera tillögur.